BridgeBio Pharma (NASDAQ: BBIO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.110 | -1.190 | -0.0800 | ||||
REV | 4.690M | 1.694M | -2.996M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of BridgeBio Pharma (NASDAQ: BBIO) through any online brokerage.
Other companies in BridgeBio Pharma’s space includes: Valneva (NASDAQ:VALN), Zentalis Pharmaceuticals (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA), Day One Biopharmaceutical (NASDAQ:DAWN) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 19.00 expecting BBIO to rise to within 12 months (a possible 91.53% upside). 13 analyst firms have reported ratings in the last year.
The stock price for BridgeBio Pharma (NASDAQ: BBIO) is $9.92 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for BridgeBio Pharma.
BridgeBio Pharma’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for BridgeBio Pharma.
BridgeBio Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.